SCHEMBL3168335

SCHEMBL3168335

O=C(c1ccc(S(=O)(=O)Nc2nccs2)cc1)N1CCCC(Cc2cncnc2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
ALDH1A1 P00352 5/20 0.48
TSHR P16473 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
USP2 O75604 2/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
STAT3 P40763 1/20 0.45
HTT P42858 1/20 0.45
HSD17B10 Q99714 1/20 0.45
SCN3A Q9NY46 2/20 0.45
MAPK1 P28482 1/20 0.45
SCN9A Q15858 2/20 0.45
CRHBP P24387 2/20 0.43
CRHR2 Q13324 2/20 0.43
NAMPT P43490 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CCNA2 P20248 1/20 0.42
CDK2 P24941 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3169403 0.88 MEN1 (0.52) MEN1KMT2AALDH1A1TSHRSMN1; SMN2
SCHEMBL3163044 0.88 KMT2A (0.51) MEN1KMT2AALDH1A1TSHRSMN1; SMN2
SCHEMBL3172220 0.86 ALDH1A1 (0.56) ALDH1A1MAPTHTTCRHBPCRHR2
SCHEMBL3162724 0.85 SCN1A (0.50) MEN1KMT2AALDH1A1TSHRSMN1; SMN2
SCHEMBL3159054 0.84 SCN3A (0.57) MEN1KMT2AALDH1A1HTTSCN3A
SCHEMBL3153864 0.83 SCN1A (0.52) KMT2AALDH1A1LMNAHTTSCN9A
SCHEMBL3163482 0.81 KMT2A (0.54) MEN1KMT2AALDH1A1LMNAHTT
SCHEMBL3262317 0.81 ALDH1A1 (0.54) MEN1KMT2AALDH1A1TSHRSMN1; SMN2
SCHEMBL3158834 0.80 KMT2A (0.51) MEN1KMT2AALDH1A1HTTSCN3A
SCHEMBL3158666 0.79 SCN9A (0.47) MEN1KMT2AALDH1A1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 MEN1 4729/4885KMT2A 1920/4885ALDH1A1 3113/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 MEN1 4729/4885KMT2A 1920/4885ALDH1A1 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.